CSL Ltd (CSL AU): Weak Vaccine Sales Affect H1FY25 Performance; FY25 Guidance Maintained

409 Views12 Feb 2025 08:30

SUMMARY

For H1FY25, CSL Ltd (CSL AU) reported net profit of $2.01B, up 6% YoY, missing estimate of $2.07B. Underlying profit (NPATA) grew 3% YoY to $2.07B.
H1FY25 revenue increased 5% YoY to $8.48B. Solid performance from CSL Behring and CSL Vifor was partially offset by negative impact from CSL Seqirus.
The company has reaffirmed FY25 underlying profit guidance of $3.2–3.3B at constant currency, up 10–13% YoY. Revenue growth is anticipated to be 5–7% YoY at constant currency.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream